Medindia

X

Faster Biotherapeutic Protein Production With the New TransIT-PRO(TM) Transfection Kit

Thursday, August 19, 2010 News on IT in Healthcare J E 4
Advertisement
MADISON, Wis., Aug. 18 Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO(TM) Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection. TransIT-PRO(TM) Kit uses animal origin free components designed for high and reproducible protein yield in suspension CHO and 293 derived cells. Since it is compatible with varied media formulations, the same media can be used for both transient and stable expression. TransIT-PRO(TM) outperforms linear PEI in protein yield and reproducibility while providing a cost-effective alternative to FreeStyle(TM) MAX.

(Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100818/CG52502LOGO)

With TransIT-PRO(TM) you will:

Visit www.mirusbio.com for all your transfection needs including access to the citations database, data, protocols, technical support, inquiries about bulk pricing or to place an order.

The Transfection Experts

More than 15 years of gene delivery expertise.

Mirus pioneered scientific breakthroughs in non-viral gene delivery. These advancements established our products as industry leading transfection reagents. At Mirus, we continue to grow our expertise in nucleic acid delivery research and products to better serve you.

-- Achieve high protein yield in suspension CHO and 293 cells -- Experience compatibility with multiple CHO media formulations -- Obtain reproducible protein expression with minimal optimization

SOURCE Mirus Bio LLC
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
GeneLink Reports Second Quarter Improvement
S
Pelosi Statement on 20th Anniversary of the Enactm...